Navigation Links
Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
Date:4/18/2013

AUSTIN, Texas, April 18, 2013 /PRNewswire/ --Savara Pharmaceuticals announced today that the first patient has started study drug treatment in a Phase 2 clinical trial evaluating the safety and efficacy of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients. AeroVanc is the first inhaled antibiotic being developed to address the growing population of MRSA lung-infected CF patients.

Persistent MRSA lung infection in CF patients has been associated with increased use of intravenous (IV) antibiotics, increased hospitalizations, faster decline of lung function, as well as shortened life-expectancy. Persistent MRSA lung infection in CF patients is difficult to eradicate or manage using oral or IV antibiotics, and there is no standard of care to manage the infection in CF patients. IV vancomycin is the antibiotic of choice for acute exacerbations of MRSA lung infections in CF patients, but the burden related to IV administration, as well as poor penetration of vancomycin into the lungs and systemic toxicities, limit its use in a chronic setting. In contrast to the established treatment of Pseudomonas aeruginosa lung infection with inhaled antibiotics, there is no FDA-approved inhaled antibiotic treatment available for MRSA lung infection.

Savara's Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study in 80 CF patients at 22 CF centers nationwide. Patients will receive either 32 mg or 64 mg doses of AeroVanc or a corresponding placebo twice daily for 28 days. The primary objective of the study is to evaluate the efficacy of AeroVanc in reducing the quantity of MRSA colony forming units in the sputum cultures. The secondary objectives include evaluation of the efficacy of AeroVanc in improving lung function, reducing respiratory symptoms reported by the patients, and reducing the use of other antibiotics. Study results are expected in the first quarter of 2014.

"We are encouraged by the recent FDA approval of Novartis' dry-powder TOBI Podhaler for Pseudomonas aeruginosa infections in CF patients. An inhaled dry powder form of vancomycin for MRSA infection will be a logical addition to this and other treatment options available for CF patients," said Rob Neville , CEO of Savara Pharmaceuticals. "We are further encouraged by the strong interest and support of key opinion leaders, and the feedback that AeroVanc is exactly what the CF care community has been waiting for."  

Details of the AeroVanc Phase 2 study can be found at www.clinicaltrials.gov (study identifier NCT01746095).

About AeroVanc

Intravenous vancomycin is the antibiotic of choice for MRSA-related bronchopneumonia, however, the burden of IV administration, poor penetration into the lungs and systemic toxicities limit its use in a chronic setting. AeroVanc (vancomycin hydrochloride inhalation powder) is a proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. By targeting vancomycin directly to the lungs, AeroVanc is expected to improve clinical efficacy and reduce side effects due to systemic drug exposure.

About Cystic Fibrosis

Cystic fibrosis is a life-shortening genetic disease characterized by thick, sticky mucus in the lungs and frequent lung infections, which result in loss of lung function. As the disease progresses, the lungs of CF patients are typically infected with bacteria that are difficult to eradicate. Physicians have been using nebulized antibiotics to treat these infections and have sought new options for treatment in the chronic care setting. The first successful reformulation of an antibiotic into dry powder inhaled therapy is the recently FDA-approved TOBI Podhaler (tobramycin inhalation powder) for Pseudomonas aeruginosa infections in CF patients. Infection by MRSA has become increasingly common with a prevalence of almost 30 percent of the estimated 30,000 CF patients in the U.S. 

About Savara Pharmaceuticals

Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. The company's lead product, AeroVanc, is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis. Savara receives funding for development of AeroVanc from the National Heart, Lung and Blood Institute of the National Institutes of Health under Award Number R44HL112393. The award spans 30 months and is subject to continued progression of the AeroVanc program. For more information about the company, please visit www.savarapharma.com.


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Tech Coast Angels Contributes More Than $3 Million to $16 Million Savara Pharmaceuticals Series B
2. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
3. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
4. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
5. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
6. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
7. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
8. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
9. JHP Pharmaceuticals to Produce Supplies of Biologic Drug Product for Late-Phase Clinical Trials
10. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
11. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves to ... progress molecular radiotherapy imaging. In molecular radiotherapy (MRT) ... quantify the radiation absorbed by those patients undergoing treatment. As ... radiotherapy treatment has been available — that is, until now. ... ...
(Date:7/5/2017)... -- Pace Analytical, a company of over 2,000 employees and a leader in ... Lab Sciences, further solidifying their position as the top American owned and operated ... ... Pace Analytical ... Mt Juliet, TN , enhances Pace Analytical,s capability as an innovative ...
(Date:7/1/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... be broadcast live over the Internet on Thursday, July 27, ... the quarterly results will be made available at 7:30 a.m. ... The live audio webcast can be accessed via Zimmer Biomet,s ... archived for replay following the conference call. ...
Breaking Medicine Technology:
(Date:7/20/2017)... Angeles, California (PRWEB) , ... July 19, 2017 , ... ... found that most successful weight loss surgery patients who had received a body contouring ... Area health and beauty clinic Beverly Hills Physicians (BHP), which provides both types of ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Lucky the Buffalo and Her Adventures”: a collection of heartwarming children’s ... Bieniek. Edward Steven Bieniek Jr. was born in Toledo, Ohio. He attended Woodward ... tech. He is married to a brilliant woman with a caring heart named Tiina, ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov and ... Do You Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — 1:30 ... 11, “Final Rule for Clinical Trials Registration and Results Information,” is a head-scratcher. ...
(Date:7/18/2017)... ... 18, 2017 , ... An inventor from Anacortes, Wash., knows the difficulties and ... frequent hot flashes, and I suffer from anxiety and vertigo on top of that," ... out and about." INSTA-FAN meets that need. , This device enables a woman in ...
(Date:7/18/2017)... (PRWEB) , ... July 19, 2017 , ... ... Winner for it’s Corporate Social Responsibility Initiative in the prestigious CEO World Awards®. ... leadership, innovation, organizational performance, new products and services, CEO case studies, corporate social ...
Breaking Medicine News(10 mins):